The venture capital company Ysios Capital, a member of CATALONIA.HEALTH, has announced that its investee company, Neurona Therapeutics, has closed a funding round of 102 million dollars. Some of the new and existing investors in the financing round include Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments and Spur Capital Partners.
Neurona will use the funding revenue to advance the portfolio of allogenic cell therapy candidates for chronic neurological disorders, including its main research candidate, NRTX-1001, for drug-resistant temporary mesial lobe epilepsy (MTLE), which is among the most common types of epilepsy. In an open phase 1/2 multicentre trial in adults with drug-resistant MTLE, NRTX-1001 has been well tolerated so far and has demonstrated the potential to provide substantial and lasting reduction of seizures.
Jordi Xiol, Partner of Ysios Capital and head of investment, mentioned: “Since our incorporation as investors, Neurona has demonstrated exceptional clinical and strategic progress. In just 14 months, it has achieved key milestones such as regulatory validation by the FDA and the presentation of very promising clinical results. The influx of investors like Fidelity and the continued support of top-level international funds not only benefits the company’s potential but also strengthens our confidence in its innovative approach to addressing neurological diseases with high unmet medical needs.”
Related news:
Comments